Talat Imran; Chief Executive Officer, Director; Rani Therapeutics Holdings Inc Svai Sanford; Chief Financial Officer; Rani Therapeutics Holdings Inc Welcome to the Rani fourth-quarter and full-year ...

Q4 2024 Earnings Call Transcript March 31, 2025 Rani Therapeutics Holdings, Inc. misses on earnings expectations. Reported ...

Researchers saw no benefits in terms of weight loss, diabetes remission, or surgery safety when patients received neoadjuvant semaglutide before MBS. HealthDay News — Neoadjuvant semaglutide before ...

NPM-139 treatment resulted in nearly 20% placebo-adjusted weight loss from a single administration with expected once or twice-yearly dosing NPM ... its subdermal semaglutide implant under ...

NPM-139 treatment resulted in nearly 20% placebo-adjusted weight loss from a single administration with expected once or twice-yearly dosing NPM-139 is a miniature ... its subdermal semaglutide ...

NPM-139 treatment resulted in nearly 20% placebo-adjusted weight loss from a single administration with expected once or twice-yearly dosing NPM ... containing semaglutide generated $25 billion ...

ALAMEDA, Calif., March 26, 2025 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ: VANI) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical ...

NanoPortal™ technology successfully delivers semaglutide, the active ingredient ... administration with expected once or twice-yearly dosing NPM-139 is a miniature, subdermal implant in ...

(MENAFN- GlobeNewsWire - Nasdaq) NanoPortalTM technology successfully delivers semaglutide ... with expected once or twice-yearly dosing NPM-139 is a miniature, subdermal implant in development ...

Single dose of Vivani’s NPM-139 semaglutide implant led to nearly 20% weight loss in rats, suggesting once- or twice-yearly dosing. NPM-139 showed steady semaglutide release with potential for ...